Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

MODERNA, INC. : Regulation FD Disclosure (form 8-K)

share with twitter share with LinkedIn share with facebook
09/18/2020 | 10:42am EDT

Item 7.01. Regulation FD Disclosure.

In a press article released in the September 18, 2020 print version of The Wall
Street Journal, the article reported, based upon data received from the U.S.
Centers for Disease Control and Prevention, upon potential production data for a
vaccine against the novel coronavirus (SARS-CoV-2) that was identified as
sharing characteristics with Moderna, Inc.'s (the "Company") mRNA vaccine
candidate (mRNA-1273).
The Company currently anticipates that its production of mRNA-1273 will be
approximately 20 million doses by the end of 2020. The Company currently
anticipates that total production of mRNA-1273 will be in the range of between
500 million and 1 billion doses during 2021.
Information in this Item 7.01 to this Current Report on Form 8-K shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities
of that section, nor shall such information be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
Cautionary Note Regarding Forward-Looking Statements
The Company cautions you that statements included in this Current Report on
Form 8-K and in press articles related to the Company that are not a description
of historical facts are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended, including
statements regarding the production schedule for mRNA-1273. In some cases,
forward-looking statements can be identified by terminology such as "will,"
"may," "should," "could," "expects," "intends," "plans," "aims," "anticipates,"
"believes," "estimates," "predicts," "potential," "continue," "likely," or the
negative of these terms or other comparable terminology, although not all
forward-looking statements contain these words. The forward-looking statements
in this Current Report on Form 8-K are neither promises nor guarantees, and you
should not place undue reliance on these forward-looking statements because they
involve known and unknown risks, uncertainties, and other factors, many of which
are beyond the Company's control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking statements.
These risks, uncertainties, and other factors include, among others: the fact
that there has never been a commercial product utilizing mRNA technology
approved for use; the fact that the rapid response technology in use by Moderna
is still being developed and implemented; the fact that the safety and efficacy
of mRNA-1273 has not yet been established; potential adverse impacts due to the
global COVID-19 pandemic such as delays in regulatory review, manufacturing and
supply chain interruptions, adverse effects on healthcare systems and disruption
of the global economy; and those other risks and uncertainties described under
the heading "Risk Factors" in the Company's most recent Quarterly Report on
Form 10-Q filed with the SEC and in subsequent filings made by the Company with
the SEC, which are available on the SEC's website at www.sec.gov. Except as
required by law, the Company disclaims any intention or responsibility for
updating or revising any forward-looking statements contained in this Current
Report on Form 8-K in the event of new information, future developments or
otherwise. These forward-looking statements speak only as of the date hereof.


© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
All news about MODERNA, INC.
10/23Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase
10/23Canada to invest up to C$214 mln for research into domestic-made vaccines - P..
10/23MODERNA : Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine against COV..
10/23MODERNA : Positive pre-clinical data for CureVac's COVID-19 vaccine
10/22MODERNA : hits enrollment milestone for COVID-19 vaccine trial
10/22Pfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a..
10/22MODERNA : US regulators seek advice on thorny issues as vaccines near
10/22MODERNA : Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COV..
10/22Covid-19 Vaccine Makers to Face Challenges When Recognizing Revenue
10/22MODERNA : US regulators seek advice on thorny issues as vaccines near
More news